Skip to main content
OpenTrials
Completed

NCT Number: NCT04914559

Glucose Response in Persons with Type 2 Diabetes

This will be a randomized crossover design with oral nutrition supplement interventions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Orange County Research Center

Tustin, California, 92780, United States

About this study

This will be a randomized crossover design with two oral nutrition supplement interventions. The subjects will be randomized to one of two interventions on two separate study days, one week apart.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 20-75 years
  • Type 2 diabetes controlled with diet or diet and metformin (Glucophage)
  • Hemoglobin A1C less than 9.0%
  • Fasting blood glucose less than 180 mg/dl
  • Hematocrit levels within normal limits
  • Having obtained his/her informed consent

Exclusion criteria

  • Abnormal thyroid function
  • Creatinine >2.0 mg/dl
  • Potassium <3.5 mEq/l
  • Gastrointestinal disease: ulcer, gastritis, diarrhea, gastroparesis, vomiting
  • Currently unstable diabetes or under treatment for cancer, heart disease, renal disease
  • Patients with anemia
  • Current insulin therapy or insulin therapy within the past month
  • Patient who are pregnant
  • Allergies to milk, soy or any component of the test product
  • Patient who in the investigators assessment cannot be expected to comply with treatment
  • Patients with anemia
  • Currently participating in another clinical trial

Treatment and study plan

Oral nutrition supplement - control

Other

Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat intended for use as supplemental nutrition.

Oral nutrition supplement - test

Other

Drink 1 cup of liquid nutrition product that contains protein, carbohydrate and fat designed for people living with diabetes and intended for use as supplemental nutrition.

Primary outcomes

  1. Area under the blood glucose curve

    Time frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

    Area under the blood glucose curve (AUC 0-240 minutes)

Secondary outcomes

  1. Area under the insulin curve

    Time frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

    Area under the insulin curve (AUC 0-240 minutes)

  2. Insulinogenic index

    Time frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

    Insulinogenic index (change in Ins30/change in Glu30)

Sponsors and collaborators

Lead sponsor

Société des Produits Nestlé (SPN)

Industry

Registry information

Official study title

Plasma Glucose and Insulin Response in Adults with Type 2 Diabetes Mellitus

Important dates

Study start
2021
Primary completion
2021
Study completion
2021
First posted
Jun 4, 2021
Registry last updated
Oct 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.